Program
Anti-EGFR Antibody-drug Conjugate CPO301
Also written as “SYS6010”, “SYS6010 injection” and “SYS6010 combined with Enlonstobart”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Squamous Cell Carcinoma of Head and Neck · Breast Neoplasms · Nasopharyngeal Carcinoma, led by 2 companies.
Drug pageAnti-EGFR Antibody-drug Conjugate CPO301: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Groupits history only | 1515 open or running | phase 3since Mar 12, 2025 | Jan 1, 2025 | Nov 30, 2026phase 2 · NCT07256509 |
| Conjupro Biotherapeuticsits history only | 11 open or running | phase 1since Jun 22, 2023 | Jun 22, 2023 | May 2027phase 1 · NCT05948865 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
SYS6010 (EGFR ADC)
, phase 3, as of Aug 20, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 22, 2023First study: phase 1 study in NeoplasmsNew to Conjupro BiotherapeuticsConjupro Biotherapeutics · NCT05948865 · 132 planned · United States, Canada
- Jan 1, 2025CSPC Pharmaceutical Group’s first study: phase 2 study in Breast NeoplasmsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06775236 · 410 planned
- Mar 12, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT06927986 · 380 planned · China
- Nov 13, 2025Phase 3 study in Esophageal Squamous Cell CarcinomaCSPC Pharmaceutical Group · NCT07251062 · 737 planned
- Nov 18, 20252 phase 2 studiesCSPC Pharmaceutical Group · NCT07254585, NCT07256509
- Jan 22, 20262 phase 3 studiesCSPC Pharmaceutical Group · NCT07376382, NCT07406542
- Feb 4, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07472647 · 596 planned
- Feb 4, 20262 phase 3 studiesCSPC Pharmaceutical Group · NCT07442565, NCT07417735
- May 31, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07633873 · 500 planned
- Jun 21, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07672223 · 586 planned · China
- Aug 6, 2026Phase 3 study in Squamous Cell Carcinoma of Head and NeckCSPC Pharmaceutical Group · NCT07758621 · 340 planned
- Oct 19, 2026Primary completion moved from 2026-06-30 to 2028-06-30Date moved laterphase 2 · +24 months · NCT07254585
- Oct 25, 20262 phase 3 studiesCSPC Pharmaceutical Group · NCT07925021, NCT07924111
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07256509
- Dec 12, 2026Primary completion: phase 3 study in NSCLCCSPC Pharmaceutical Group · NCT07376382
- May 2027Primary completion: phase 1 study in NeoplasmsConjupro Biotherapeutics · NCT05948865
- Jun 15, 2027Primary completion: phase 2 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT06775236
TargetBeta
“An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-EGFR ADC CPO301, the monoclonal an…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07924111Esophageal Squamous Cell Carcinoma | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 30, 2029 | 585 |
| NCT07925021Nasopharyngeal Carcinoma · China | 3 | Recruiting | CSPC Pharmaceutical Group | Oct 1, 2029 | 424 |
| NCT07758621Squamous Cell Carcinoma of Head and Neck | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Sep 15, 2028 | 340 |
| NCT07672223Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | CSPC Pharmaceutical Group | Sep 30, 2029 | 586 |
| NCT07633873Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Sep 30, 2027 | 500 |
| NCT07417735Locally Advanced/Metastatic/Recurrent ESCC | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 31, 2028 | 436 |
| NCT07472647Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Feb 28, 2029 | 596 |
| NCT07442565Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 30, 2027 | 506 |
| NCT07406542Recurrence | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Apr 1, 2029 | 400 |
| NCT07376382NSCLC | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 12, 2026 | 680 |
| NCT07256509Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Nov 30, 2026 | 120 |
| NCT07254585Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | CSPC Pharmaceutical Group | Jun 30, 2028 | 110 |
| NCT07251062Esophageal Squamous Cell Carcinoma | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 30, 2029 | 737 |
| NCT06927986Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | CSPC Pharmaceutical Group | Jul 30, 2026 | 380 |
| NCT06775236Breast Neoplasms | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 15, 2027 | 410 |
| NCT05948865Neoplasms · United States, Canada | 1 | Recruiting | Conjupro Biotherapeutics | May 2027 | 132 |
How it is read
Names in the registry
- “SYS6010”, 9 entries
- “SYS6010 injection”, 2 entries
- “SYS6010 combined with Enlonstobart”, 1 entry
- “CPO301”, 1 entry
- “SYS6090 + SYS6010”, 1 entry
Codes read as this program: SYS6010.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Esophageal Squamous Cell Carcinoma, 2 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Breast Neoplasms, 2 studies
- Nasopharyngeal Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.